These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Long non-coding RNA linc00460 promotes epithelial-mesenchymal transition and cell migration in lung cancer cells. Li K; Sun D; Gou Q; Ke X; Gong Y; Zuo Y; Zhou JK; Guo C; Xia Z; Liu L; Li Q; Dai L; Peng Y Cancer Lett; 2018 Apr; 420():80-90. PubMed ID: 29409808 [TBL] [Abstract][Full Text] [Related]
34. Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Kato Y; Hosomi Y; Watanabe K; Yomota M; Kawai S; Okuma Y; Kubota K; Seike M; Gemma A; Okamura T J Thorac Dis; 2019 Jun; 11(6):2350-2360. PubMed ID: 31372272 [TBL] [Abstract][Full Text] [Related]
35. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441 [TBL] [Abstract][Full Text] [Related]
36. Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real-world data analysis. Chang N; Duan J; Wang L; Dong Z; Liu Z Oncol Lett; 2020 Sep; 20(3):2266-2272. PubMed ID: 32782544 [TBL] [Abstract][Full Text] [Related]
37. Construction of IMMS Containing Multi-site Liposomes for Dynamic Monitoring of Blood CTC in Patients with Osimertinib-resistant Non-small-cell Lung Cancer and its Mechanism. Chen X; Luo L; Lu Y; Qiu Y; Liang J; Chen Y; Ning Y; Li B Anticancer Agents Med Chem; 2023; 23(6):676-686. PubMed ID: 36345240 [TBL] [Abstract][Full Text] [Related]
39. Effects of Linc00460 on cell migration and invasion through regulating epithelial-mesenchymal transition (EMT) in non-small cell lung cancer. Yue QY; Zhang Y Eur Rev Med Pharmacol Sci; 2018 Feb; 22(4):1003-1010. PubMed ID: 29509248 [TBL] [Abstract][Full Text] [Related]
40. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations. Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]